CERO Therapeutics Holdings, Inc. announced on May 30, 2025, that it has dosed the first patient in its Phase 1 clinical trial of CER-1236. This significant milestone marks the initiation of human studies for its lead compound, which is focused on patients with acute myeloid leukemia (AML).
The patient was dosed at the lead trial site, and monitoring is currently underway for key safety, tolerability, and efficacy endpoints, more than seven days post-infusion. The study protocol will be featured in a poster presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), held from May 30 to June 3, 2025.
Robert Sikorski, M.D., Ph.D., CERO Therapeutics’ Chief Medical Officer, remarked that the completion of first-in-human dosing represents a crucial clinical development milestone for CER-1236, a novel autologous CAR-T therapeutic candidate. The company anticipates communicating results as data matures from the ongoing protocol-specified evaluations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.